カテゴリ： GlobalData, デンマーク, 企業調査

H. Lundbeck AS (LUN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：H. Lundbeck AS (LUN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9895
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：99
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：デンマーク
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) diseases including psychiatric and neurological disorders. Its products are indicated for the treatment of diseases such as Alzheimer’s disease, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington’s disease, among others. The company operates production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies and hospitals in Europe, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

H. Lundbeck AS (LUN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 15
Venture Financing 17
Naurex Raises USD80 Million in Series C Venture Financing 17
Naurex Raises US$25 Million In Venture Financing 19
Naurex Raises US$38 Million In Series B Financing 21
Partnerships 23
Confo Therapeutics Enters into Agreement with H. Lundbeck 23
Cerveau Technologies Enters into Research Agreement with Lundbeck 24
H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25
Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26
H. Lundbeck Enters into Agreement with IBM Watson Health 27
Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28
Ossianix Expands and Extends Research Agreement with Lundbeck 29
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30
Ossianix Enters Into Co-Development Agreement With Lundbeck 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36
Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer’s Disease 37
Licensing Agreements 38
MindImmune Therapeutics Enters into Licensing Agreement with Lundbeck 38
Lundbeck Enters into Licensing Agreement with Vanderbilt University 39
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 40
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 41
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 42
Equity Offering 43
H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 43
H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 44
Chelsea Therapeutics Completes Public Offering Of Shares For US$23 Million 45
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of US$100 Million 46
Chelsea Therapeutics Completes Public Offering Of Common Stock For US$24 Million 47
Asset Transactions 49
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 49
Acquisition 51
Lundbeck Acquires Prexton Therapeutics 51
H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 52
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 54
H. Lundbeck AS – Key Competitors 55
H. Lundbeck AS – Key Employees 56
H. Lundbeck AS – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Recent Developments 61
Financial Announcements 61
Nov 07, 2018: Lundbeck realized 12% growth in revenue and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised 61
Aug 08, 2018: Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS 62
May 08, 2018: Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS 76
Feb 07, 2018: Lundbeck delivers its best financial results following 10% revenue growth and 117% growth in net profit 77
Nov 08, 2017: Lundbeck increased operating profit (EBIT) with 126% and EPS by 182% in the first nine months of 2017 78
Aug 09, 2017: Lundbeck reports 13% revenue growth and a doubling of EBIT in first half of 2017 79
May 10, 2017: Lundbeck: 2017 guidance raised based on strong revenue growth and improved profitability 86
Feb 08, 2017: Lundbeck continues to show solid revenue growth and strong improvement in profitability 87
Corporate Communications 88
Jul 02, 2018: H. Lundbeck Appoints Dr. Deborah Dunsire As President And CEO 88
Mar 20, 2018: Lundbeck held its Annual General Meeting on 20 March 2018 at the company’s registered office 89
Oct 30, 2017: Changes to Lundbeck’s Executive Management 90
Sep 11, 2017: Changes in Executive Management in Lundbeck 91
Product News 92
Dec 02, 2017: Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS) 92
Aug 02, 2017: 23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar Disorders 93
Apr 18, 2017: Lundbeck to Present Data on Movement Disorder and Epilepsy Therapies at AAN Annual Meeting 94
03/20/2018: Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech 95
Mar 03, 2017: Bioneer: In the Forefront of Developing New Human Cell Models for Neurodegenerative Diseases 96
Clinical Trials 97
Jun 25, 2018: Lundbeck starts clinical development of potential new treatment of Parkinson’s disease 97
Jul 10, 2017: Parkinson’s disease: Prexton announces initiation of phase II clinical testing 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99

List of Tables
H. Lundbeck AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
H. Lundbeck AS, Deals By Therapy Area, 2012 to YTD 2018 10
H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 15
Naurex Raises USD80 Million in Series C Venture Financing 17
Naurex Raises US$25 Million In Venture Financing 19
Naurex Raises US$38 Million In Series B Financing 21
Confo Therapeutics Enters into Agreement with H. Lundbeck 23
Cerveau Technologies Enters into Research Agreement with Lundbeck 24
H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25
Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26
H. Lundbeck Enters into Agreement with IBM Watson Health 27
Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28
Ossianix Expands and Extends Research Agreement with Lundbeck 29
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30
Ossianix Enters Into Co-Development Agreement With Lundbeck 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36
Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer’s Disease 37
MindImmune Therapeutics Enters into Licensing Agreement with Lundbeck 38
Lundbeck Enters into Licensing Agreement with Vanderbilt University 39
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 40
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 41
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 42
H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 43
H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 44
Chelsea Therapeutics Completes Public Offering Of Shares For US$23 Million 45
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of US$100 Million 46
Chelsea Therapeutics Completes Public Offering Of Common Stock For US$24 Million 47
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 49
Lundbeck Acquires Prexton Therapeutics 51
H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 52
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 54
H. Lundbeck AS, Key Competitors 55
H. Lundbeck AS, Key Employees 56
H. Lundbeck AS, Subsidiaries 57

List of Figures
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[H. Lundbeck AS (LUN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • NWF Group plc (NWF)：企業の財務・戦略的SWOT分析
    Summary NWF Group Plc (NWF) is a consumer goods company that offers animal feedstuffs products. The company operates through feeds, food and fuel segments. It offers products such as fuel oil, dairy products, animal feeds and agricultural products. Its offers fuel, food and feed business solutions. …
  • Wien Energie GmbH：企業の戦略的SWOT分析
    Wien Energie GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Galadari Hotels (Lanka) PLC ：企業の戦略・SWOT・財務情報
    Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report Summary Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • GlaxoSmithKline Plc (GSK)：企業の財務・戦略的SWOT分析
    GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Iamgold Corporation：企業の戦略・SWOT・財務情報
    Iamgold Corporation - Strategy, SWOT and Corporate Finance Report Summary Iamgold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Gulf Keystone Petroleum Ltd (GKP)：石油・ガス：M&Aディール及び事業提携情報
    Summary Gulf Keystone Petroleum Ltd (Gulf Keystone) is an oil and gas company that offers operation and production of oil and natural gas reserves. The company operates working interests in the Republic of Algeria and the Kurdistan Region of Northern Iraq. Its Kurdistan Region of Iraq operates produ …
  • CooperVision Inc-医療機器分野：企業M&A・提携分析
    Summary CooperVision Inc (CooperVision), a subsidiary of The Cooper Companies Inc, designs and manufactures soft contact lenses. It manufactures a wide array of monthly, two-week and daily disposable contact lenses. CooperVision helps overcome various vision challenges such as astigmatism and presby …
  • Grupo Aval Acciones y Valores S.A.：戦略・SWOT・企業財務分析
    Grupo Aval Acciones y Valores S.A. - Strategy, SWOT and Corporate Finance Report Summary Grupo Aval Acciones y Valores S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • China General Technology (Group) Holding Ltd：企業の戦略・SWOT・財務情報
    China General Technology (Group) Holding Ltd - Strategy, SWOT and Corporate Finance Report Summary China General Technology (Group) Holding Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • TxCell SA (TXCL)：企業の財務・戦略的SWOT分析
    Summary Txcell SA (Txcell) a subsidiary of Sangamo Therapeutics Inc, is a biotechnology company that develops personalized cellular immunotherapies using regulatory T cells (Treg) for the treatment of autoimmune and inflammatory diseases as well as transplantation-related inflammatory disorders. The …
  • Luminex Corp (LMNX)：企業の財務・戦略的SWOT分析
    Luminex Corp (LMNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Singapore Airlines Ltd：企業のM&A・事業提携・投資動向
    Singapore Airlines Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Singapore Airlines Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • ROHM Co Ltd (6963)：企業の財務・戦略的SWOT分析
    ROHM Co Ltd (6963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Actuant Corporation：企業のM&A・事業提携・投資動向
    Actuant Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Actuant Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Grupo Famsa, S.A.B. de C.V.：戦略・SWOT・企業財務分析
    Grupo Famsa, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Grupo Famsa, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Acceleron Pharma Inc (XLRN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Acceleron Pharma Inc (Acceleron Pharma) is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutics to treat serious and rare diseases. The company’s lead therapeutic candidate, luspatercept, is in phase 3 studyused for the treatment of the myelodys …
  • Dyo Boya Fabrikalari Sanayi ve Tic. A.S. (DYOBY)：企業の財務・戦略的SWOT分析
    Dyo Boya Fabrikalari Sanayi ve Tic. A.S. (DYOBY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Mitsui O.S.K. Lines Ltd (9104)：企業の財務・戦略的SWOT分析
    Mitsui O.S.K. Lines Ltd (9104) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Alamo Group Inc (ALG)：企業の財務・戦略的SWOT分析
    Alamo Group Inc (ALG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Alviva Holdings Ltd (AVV)：企業の財務・戦略的SWOT分析
    Alviva Holdings Ltd (AVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆